Aziz, Mina D. and Shah, Jay and Kapoor, Urvi and Dimopoulos, Christina and Anand, Sarah and Augustine, Allan and Ayuk, Francis and Chaudhry, Mohammed and Chen, Yi-Bin and Choe, Hannah K. and Etra, Aaron and Gergoudis, Stephanie and Hartwell, Matthew J. and Hexner, Elizabeth O. and Hogan, William J. and Kitko, Carrie L. and Kowalyk, Steven and Kroeger, Nicolaus and Merli, Pietro and Morales, George and Nakamura, Ryotaro and Ordemann, Rainer and Pulsipher, Michael A. and Qayed, Muna and Reshef, Ran and Roesler, Wolf and Schechter, Tal and Schreiner, Elisabeth and Srinagesh, Hrishikesh and Woelfl, Matthias and Wudhikarn, Kitsada and Yanik, Gregory and Young, Rachel and Ozbek, Umut and Ferrara, James L. M. and Levine, John E. (2020) Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. LEUKEMIA, 34 (7). pp. 1898-1906. ISSN 0887-6924, 1476-5551
Full text not available from this repository. (Request a copy)Abstract
The graft-versus-leukemia (GVL) effect after allogeneic hematopoietic cell transplant (HCT) can prevent relapse but the risk of severe graft-versus-host disease (GVHD) leads to prolonged intensive immunosuppression and possible blunting of the GVL effect. Strategies to reduce immunosuppression in order to prevent relapse have been offset by increases in severe GVHD and nonrelapse mortality (NRM). We recently validated the MAGIC algorithm probability (MAP) that predicts the risk for severe GVHD and NRM in asymptomatic patients using serum biomarkers. In this study we tested whether the MAP could identify patients whose risk for relapse is higher than their risk for severe GVHD and NRM. The multicenter study population (n = 1604) was divided into two cohorts: historical (2006-2015, n = 702) and current (2015-2017, n = 902) with similar NRM, relapse, and survival. On day 28 post-HCT, patients who had not developed GVHD (75% of the population) and who possessed a low MAP were at much higher risk for relapse (24%) than severe GVHD and NRM (16 and 9%); this difference was even more pronounced in patients with a high disease risk index (relapse 33%, NRM 9%). Such patients are good candidates to test relapse prevention strategies that might enhance GVL.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | VERSUS-HOST-DISEASE; MINIMAL RESIDUAL DISEASE; LOW-DOSE CYCLOSPORINE; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; IMMUNE SUPPRESSION; PROPHYLAXIS; SURVIVAL; DONOR; RECIPIENTS; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 09 Apr 2021 08:17 |
| Last Modified: | 09 Apr 2021 08:17 |
| URI: | https://pred.uni-regensburg.de/id/eprint/45149 |
Actions (login required)
 |
View Item |
